Overlap between irritable bowel syndrome and inflammatory bowel disease

Digestive Diseases

Volumn 27, Issue SUPPL. 1, 2010, Pages 48-54

  Spiller, Robin C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Inflammation; Mast cells; Permeability; Stress

Indexed keywords

CALGRANULIN; CORTICOTROPIN RELEASING FACTOR; CROMOGLYCATE DISODIUM; HISTAMINE; HORSERADISH PEROXIDASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; MESALAZINE; MESSENGER RNA; NEUROPEPTIDE; PREDNISOLONE; PROTEINASE; SEROTONIN; SEROTONIN 5 RECEPTOR;

ABDOMINAL PAIN; ACUTE GASTROENTERITIS; ANXIETY; CAMPYLOBACTER ENTERITIS; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL HYPERPLASIA; CELL PROLIFERATION; COLON; COLON MUCOSA; CONFERENCE PAPER; CYTOKINE PRODUCTION; DEPRESSION; DIARRHEA; DISEASE DURATION; ENTERITIS; ENTEROCHROMAFFIN CELL; ENTEROENDOCRINE CELL; EOSINOPHIL; FLUOROSCOPY; FOOD ALLERGY; HUMAN; HYPERSENSITIVITY; ILEUM; INTESTINE DISTENSION; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LYMPHOCYTE; MACROPHAGE ACTIVATION; MAST CELL; MICROFLORA; MUCOSA INFLAMMATION; MYENTERIC PLEXUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOTODERMATOSIS; PRIORITY JOURNAL; T LYMPHOCYTE; URINARY URGENCY; VISCERA;

ANIMALS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PERMEABILITY;

EID: 77950812787     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000268121     Document Type: Conference Paper

References (48)

1. Fass R, Naliboff BD, Fass SS, Peleg N, Wendel C, Malagon IB, et al: The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. Gastroenterology 2008; 134: 696-705.
2. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H: Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601-607.
3. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr: Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993;38: 1590-1595.
4. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, et al: Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-457.
5. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, et al: The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-406.
6. Neal KR, Hebden J, Spiller R: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med J 1997; 314: 779-782.
7. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, et al: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811.
8. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783.
9. Dunlop SP, Jenkins D, Spiller RC: Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1578-1583.
10. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De GR, et al: Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
11. Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, et al: Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007; 56: 1706-1713.
12. Heaton KW, Ghosh S, Braddon FE: How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991; 32: 73-79.
13. Pimentel M, Hwang L, Melmed GY, Low K, Vasiliauskas E, Ippoliti A, et al: New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. Dig Dis Sci 2010;55:145-149.
14. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, et al: Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523-526.
15. Wang LH, Fang XC, Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-1101.
16. Campbell E, Richards M, Foley S, Hastings M, Whorwell P, Mahida Y, et al: Markers of inflammation in IBS: increased permeability and cytokine production in diarrhoea predominant subgroups (abstract). Gastroenterology 2006; 130:A51.
17. Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, et al: Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920.
18. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM: Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20: 1317-1322.
19. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, et al: Abnormal intestinal permeability in subgroups of diarrheapredominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-1294.
20. Zhou Q, Zhang B, Nicholas Verne G: Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 41-46.
21. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-93. (Pubitemid 36020772)
22. Drossman DA, McKee DC, Sandler RS, Mitchell CM, Cramer EM, Lowman BC, et al: Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988; 95: 701-708.
23. Sykes MA, Blanchard EB, Lackner J, Keefer L, Krasner S: Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J Behav Med 2003; 26: 361-372.
24. Santos J, Yang PC, Soderholm JD, Benjamin M, Perdue MH: Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut 2001; 48: 630-636.
25. Soderholm JD, Yang PC, Ceponis P, Vohra A, Riddell R, Sherman PM, et al: Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 2002; 123: 1099-1108.
26. Spiller RC: Role of infection in irritable bowel syndrome. J Gastroenterol 2007; 42(suppl 17):41-47.
27. Garsed K, Spiller R: Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988.
28. Santos J, Saperas E, Nogueiras C, Mourelle M, Antolin M, Cadahia A, et al: Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology 1998; 114: 640-648.
29. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, et al: Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-209. (Pubitemid 46246208)
30. Foley S, Coleman N, Holmes GKT, Bennett A, Spiller RC: Increased intra-epithelial lymphocytes and mast cells with depressed serotonin transporter in duodenal biopsies and platelets of patients with INS and diarrhoea (IBS-D): correlation with bowel frequency. Gastroenterology 2008; 134(suppl 1):A-41.
31. Wallon C, Yang PC, Keita AV, Ericson AC, McKay DM, Sherman PM, et al: Corticotropin- releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008; 57: 50-58.
32. Camilleri M, McKinzie S, Busciglio I, Low PA, Sweetser S, Burton D, et al: Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772-781.
33. Barbara G, Wang B, Stanghellini V, De Giorgio R, Cremon C, Di Nardo G, et al: Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37. (Pubitemid 46108761)
34. Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, et al: Activation of human enteric neurons by supernatants of colonic biopsies from patients with irritable bowel syndrome. Gastroenterology 2009; 137: 1425-1434.
35. Foley KF, Pantano C, Ciolino A, Mawe GM: IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in Caco2 cells. Am J Physiol Gastrointest Liver Physiol 2007; 292:G779-G784. (Pubitemid 46440381)
36. Linden DR, Foley KF, McQuoid C, Simpson J, Sharkey KA, Mawe GM: Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. Neurogastroenterol Motil 2005; 17: 565-574. (Pubitemid 41075999)
37. Keating C, Beyak M, Foley S, Singh G, Marsden C, Spiller R, et al: Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism. J Physiol 2008; 586: 4517-4530.
38. Cremonini F, Delgado-Aros S, Camilleri M: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86. (Pubitemid 36313138)
39. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P: Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and metaanalysis. Gut 2009; 58: 367-378.
40. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, et al: Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31. (Pubitemid 36799103)
41. Dunlop SP, Jenkins D, Neal KR, Naesdal J, Borgaonker M, Collins SM, et al: Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 77-84. (Pubitemid 36897983)
42. Aron J: Response to mesalamine and balazide in patients with irritable bowel syndrome refractory to alosetron and tegaserod (abstract). Gastroenterology 2005; 128:A329.
43. Andrews C, Petcy R, Griffiths T, Bjarnason K, Champan K, Cellars L, et al: Mesalazine alters colonic mucosal protealitic activity and faecal bacterial profiles in diarhoea predominant irritable bowel syndrome (IBS-D). Gastroenterology 2008; 134(4 suppl 1):A548.
44. Bafutto M, Almeida JR, Almeida RC, Almeida TC, Leite NV, Rezende-Filho J: Treatment of post infectious irritable bowel syndrome and non infective irritable bowel syndrome with mesalazine. Gastroenterology 2008; 134(4 suppl 1):A672.
45. Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, et al: Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study. Aliment Pharmacol Ther 2009; 30: 245-252.
46. Tuteja A, Hale D, Stoddard G, Fang J, Tolman K: Double-blind placebo controlled study of mesalamine in post-infective irritable bowel syndrome. Am J Gastroenterol 2008; 103: 1227.
47. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein A, Brandt L, et al: The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut DOI: 10.1136/gut.2008.167270.
48. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551. (Pubitemid 40585355)